title: Glargine versus NPH insulin in cystic fibrosis related diabetes.
abstract: BACKGROUND
  Cystic fibrosis related diabetes (CFRD) with fasting hyperglycemia is found in 15% of adult and 11% of adolescent CF patients. Because of concerns about hypoglycemia, it is not common practice to treat CFRD with 24-hour basal insulin therapy, despite evidence that insulin deficiency may contribute to protein catabolism and have an adverse effect on weight, muscle mass, pulmonary function, and, ultimately, survival. We hypothesized that insulin glargine would improve blood glucose control and weight in patients with CFRD without causing hypoglycemia.
  
  
  METHODS
  A randomized cross-over study compared 12 weeks each of bedtime NPH or glargine in 19 CFRD patients.
  
  
  RESULTS
  There was significantly greater reduction in fasting plasma glucose with glargine (P=0.03), and participants showed a non-significant trend towards weight gain with this insulin (P=0.07). No serious hypoglycemia occurred. At study end, all patients chose to continue glargine.
  
  
  CONCLUSIONS
  A study of longer duration is needed to determine whether insulin glargine impacts protein catabolism and overall clinical status in CF patients, but these initial data suggest that this is a promising therapy in CFRD.
authors: Department of Pediatrics, School of Medicine, University of Minnesota, Minneapolis, MN 55454, United States.
authors: Patricia
authors: P
authors: Grover
authors: William
authors: W
authors: Thomas
authors: Antoinette
authors: A
authors: Moran
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000627:therapeutic use*; D049528:Insulin, Long-Acting; D008297:Male; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D007336:Insulin, Isophane
references: Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):891-5
references: 10988101
references: J Pediatr. 1988 Mar;112(3):373-7
references: 3346774
references: Diabetes Care. 2005 Sep;28(9):2141-4
references: 16123480
references: Pediatrics. 1998 Mar;101(3 Pt 1):433-7
references: 9481010
references: Diabetes Res Clin Pract. 1999 Aug;45(1):61-73
references: 10499886
references: Metabolism. 2004 Nov;53(11):1467-72
references: 15536603
references: J Pediatr. 1998 Jul;133(1):10-17
references: 9672504
references: Diabetes. 2001 Jun;50(6):1336-43
references: 11375334